Related Experiment Video
Updated: Sep 17, 2025

Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Identification of Therapeutic Targets for Osteoporosis through Multiomics Integration and the Potential Dual Role of
Jun Du1, Minjun Chang2, Kunlong Jiang2
1Department of Orthopedic Magnetic Resonance Chamber, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Suzhou 215000, China.
Abstract:
This study investigates potential therapeutic targets for osteoporosis using a multiomics approach and explores the dual role of androgen receptor (AR) signaling in its pathophysiology. By analyzing single-cell RNA sequencing data (GSE147287), we identified nine major cell types and their specific developmental trajectories in osteoporosis samples. Differential miRNA analysis revealed 19 significantly dysregulated miRNAs, and integrated database analysis identified six hub genes, including AR, which is highly expressed in tissue stem cells. Further pathway analysis highlighted the involvement of AR in myeloid cell activation and osteoclast differentiation, key processes in bone resorption. We also constructed a drug-gene-miRNA interaction network, identifying potential interactions between AR and drugs such as norethisterone (AR agonist) and cyproterone acetate (AR antagonist). DeepPurpose analysis, drug MoA, and molecular docking predictions indicated that cyproterone acetate exhibited a stronger binding affinity to AR and could inhibit overactivation of AR signaling, offering a more effective therapeutic option than norethisterone. In vitro experiments confirmed that both drugs inhibited RANKL-induced osteoclastogenesis, with cyproterone acetate showing superior efficacy at lower concentrations. This work provides preliminary evidence for the dual role of AR signaling in osteoporosis and suggests that targeting AR with antagonists (cycloacetate) could be a promising strategy for treating bone resorption.
Insights
This study reveals the androgen receptor's (AR) dual role in osteoporosis, identifying AR antagonists as promising treatments. Targeting AR signaling with drugs like cyproterone acetate may effectively combat bone resorption.
Area of Science:
- Biomedical research
- Genomics
- Pharmacology
Background:
- Osteoporosis involves complex cellular and molecular mechanisms.
- Androgen receptor (AR) signaling is implicated in bone pathophysiology, but its precise role is not fully understood.
Purpose of the Study:
- To investigate potential therapeutic targets for osteoporosis using a multiomics approach.
- To explore the dual role of androgen receptor (AR) signaling in osteoporosis.
- To identify effective drug candidates for treating bone resorption.
Main Methods:
- Analysis of single-cell RNA sequencing data (GSE147287) to identify cell types and developmental trajectories.
- Differential miRNA analysis and integrated database analysis to identify hub genes.
- Construction of drug-gene-miRNA interaction networks, including DeepPurpose analysis, drug MoA, and molecular docking.
- In vitro experiments to assess drug efficacy on osteoclastogenesis.
Main Results:
- Nine major cell types and their trajectories were identified in osteoporosis samples.
- Nineteen dysregulated miRNAs and six hub genes, including AR, were identified.
- AR is highly expressed in tissue stem cells and involved in myeloid cell activation and osteoclast differentiation.
- Cyproterone acetate (AR antagonist) showed stronger binding affinity to AR and superior inhibition of osteoclastogenesis compared to norethisterone (AR agonist).
Conclusions:
- Androgen receptor (AR) signaling plays a dual role in osteoporosis pathophysiology.
- Targeting AR with antagonists, such as cyproterone acetate, presents a promising therapeutic strategy for osteoporosis and bone resorption.
More Related Videos
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling
Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Signal Transduction: Overview
Typically, signal transduction involves three...

